Opportunity Information: Apply for PA 12 221
Apply for PA 12 221
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Biomarkers for Early Detection of Hematopoietic Malignancies (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393 Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research.
- This funding opportunity was created on Jun 28, 2012 and posted on Jun 28, 2012.
- Applicants must submit their applications by Sep 7, 2015. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Public and State controlled institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) City or township governments Public housing authorities/Indian housing authorities Special district governments Native American tribal governments (Federally recognized) Independent school districts Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments Private institutions of higher education For profit organizations other than small businesses Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Biomarkers for Early Detection of Hematopoietic Malignancies (R01)" (Funding Opportunity Number PA-12-221) was a National Cancer Institute (NCI) Funding Opportunity Announcement under the National Institutes of Health (NIH). It used the R01 research project grant mechanism and focused on supporting investigator-initiated research aimed at improving how blood-related cancers are identified early, monitored over time, and assessed for future risk. The overall intent was to move biomarker research beyond discovery alone and toward development, refinement, and validation of measurable indicators that can be used more reliably for clinically meaningful questions in hematopoietic malignancies.
The scientific emphasis of the FOA centered on two main needs. First, it encouraged projects that develop and validate biomarkers for early detection of hematopoietic malignancies, as well as biomarkers that can help predict disease progression or detect recurrence, with particular interest in applications for individuals who are considered high-risk. Second, it encouraged biomarker approaches for risk assessment, including both primary hematopoietic malignancies (first cancers arising in the blood or lymph system) and secondary hematopoietic malignancies (for example, cancers that may occur after prior cancer therapy or other exposures). In practical terms, the FOA was looking for research that could help identify who is likely to develop disease, who is likely to progress from an early or precursor state to overt malignancy, and who might be experiencing relapse earlier than standard methods can detect.
In addition to biomarker identification and validation, the FOA also highlighted technology and methods development as a priority. It explicitly encouraged the development and improvement of specific technologies and quantitative methods capable of detecting novel biomarkers associated with hematopoietic malignancies. This point matters because many promising biomarkers fail to translate due to inadequate assay performance, lack of reproducibility, insufficient sensitivity for low-level disease detection, or difficulty standardizing measurements across settings. By emphasizing quantitative detection methods, the announcement signaled interest in tools and platforms that can measure biomarkers with accuracy, precision, and consistency, especially in contexts where signals may be subtle or present at very low levels.
Administratively, the opportunity fell under the discretionary grant category and was associated with NIH/NCI program areas related to cancer cause and prevention research (CFDA 93.393) and cancer detection and diagnosis research (CFDA 93.394). There was no cost sharing or matching requirement, which is typical for many NIH research grants and reduces barriers for applicants who might otherwise need to provide institutional matching funds.
Eligibility was broad and included a wide range of U.S. and non-U.S. organizations. Eligible applicants included public and private institutions of higher education, state and local governments (including counties, cities, special districts, and independent school districts), tribal governments and tribally controlled organizations, public housing authorities/Indian housing authorities, nonprofits both with and without 501(c)(3) status (with the usual NIH distinctions for higher education), small businesses, and for-profit organizations other than small businesses. The FOA also explicitly recognized eligibility for organizations such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian-serving institutions, tribally controlled colleges and universities (TCCUs), faith-based and community-based organizations, and U.S. territories or possessions. Importantly, foreign institutions were eligible to apply, and foreign components of U.S. organizations were allowed, consistent with NIH policy when a project can be justified scientifically and programmatically.
Timeline information indicates the FOA was posted and created on June 28, 2012, with an original and final closing date of September 7, 2015, and it was archived on October 8, 2015. This means the announcement is no longer active for new applications under that specific FOA number, though similar scientific topics may appear in newer NIH/NCI funding opportunities.
For reference and documentation, the announcement provided an NIH Grants Guide link to the full FOA text (http://grants.nih.gov/grants/guide/pa-files/PA-12-221.html). It also listed NIH Office of Extramural Research (OER) webmaster contacts for access or linking issues (FBOWebmaster@OD.NIH.GOV), indicating that technical assistance was available for applicants who had trouble retrieving the full posting.
Frequently Asked Questions (FAQs)
What is the title and funding opportunity number for this grant?
The opportunity is titled Biomarkers for Early Detection of Hematopoietic Malignancies (R01) and the Funding Opportunity Number is PA-12-221.
Which agencies offered this funding opportunity?
This was a National Cancer Institute (NCI) Funding Opportunity Announcement under the National Institutes of Health (NIH).
What type of grant mechanism did this opportunity use?
What scientific area did this FOA focus on?
The FOA focused on biomarker research for hematopoietic malignancies (blood-related cancers), with an emphasis on improving how these diseases are detected early, monitored over time, and assessed for future risk.
What was the overall intent of the announcement?
The overall intent was to move biomarker work beyond discovery alone and toward the development, refinement, and validation of measurable indicators that can be applied more reliably to clinically meaningful questions in hematopoietic malignancies.
What were the two main scientific needs emphasized by the FOA?
The FOA emphasized two main needs:
- Biomarkers for early detection and monitoring: development and validation of biomarkers for early detection of hematopoietic malignancies, prediction of disease progression, and detection of recurrence, with particular interest in use for high-risk individuals.
- Biomarkers for risk assessment: biomarker approaches for risk assessment in both primary hematopoietic malignancies and secondary hematopoietic malignancies (such as those occurring after prior cancer therapy or other exposures).
What kinds of research questions was the FOA trying to enable?
In practical terms, the FOA sought research that could help:
- Identify who is likely to develop a hematopoietic malignancy
- Determine who is likely to progress from an early or precursor state to overt malignancy
- Detect relapse earlier than standard methods
Was the FOA limited to biomarker discovery?
No. While biomarkers were central, the announcement explicitly pushed beyond discovery and encouraged development, refinement, and validation so biomarkers could be used more reliably for clinically meaningful applications.
Did the FOA emphasize technology or methods development?
Yes. The FOA explicitly encouraged technology and methods development, including developing and improving specific technologies and quantitative methods to detect novel biomarkers associated with hematopoietic malignancies.
Why did the FOA highlight quantitative detection methods?
The FOA noted that many promising biomarkers fail to translate due to issues like inadequate assay performance, poor reproducibility, insufficient sensitivity for low-level disease detection, or difficulty standardizing measurements across settings. By emphasizing quantitative detection methods, the FOA signaled interest in tools that measure biomarkers with accuracy, precision, and consistency, especially when biomarker signals may be subtle or present at very low levels.
Did the FOA show particular interest in any patient groups?
Yes. The FOA expressed particular interest in biomarker applications for people considered high-risk.
Did the FOA cover both primary and secondary hematopoietic malignancies?
Yes. The FOA encouraged biomarker approaches for risk assessment in both:
- Primary hematopoietic malignancies (first cancers arising in the blood or lymph system)
- Secondary hematopoietic malignancies (for example, cancers that may occur after prior cancer therapy or other exposures)
What grant category was this opportunity associated with?
The opportunity fell under the discretionary grant category.
Which NIH/NCI program areas (CFDA) were associated with this FOA?
The FOA was associated with NIH/NCI program areas related to:
- Cancer Cause and Prevention Research (CFDA 93.393)
- Cancer Detection and Diagnosis Research (CFDA 93.394)
Was cost sharing or matching required?
No. The FOA stated there was no cost sharing or matching requirement.
Who was eligible to apply?
Eligibility was broad and included a wide range of U.S. and non-U.S. organizations. Eligible applicants included:
- Public and private institutions of higher education
- State and local governments (including counties, cities, special districts, and independent school districts)
- Tribal governments and tribally controlled organizations
- Public housing authorities/Indian housing authorities
- Nonprofits (with and without 501(c)(3) status, with the usual NIH distinctions for higher education)
- Small businesses
- For-profit organizations other than small businesses
- U.S. territories or possessions
Were foreign organizations eligible?
Yes. Foreign institutions were eligible to apply, and foreign components of U.S. organizations were allowed, consistent with NIH policy when scientifically and programmatically justified.
Did the FOA explicitly recognize minority-serving and community-based organizations?
Yes. The FOA explicitly recognized eligibility for organizations such as:
- Historically Black Colleges and Universities (HBCUs)
- Hispanic-serving institutions
- Alaska Native and Native Hawaiian-serving institutions
- Tribally controlled colleges and universities (TCCUs)
- Faith-based and community-based organizations
When was this FOA posted and when did it close?
The FOA was posted and created on June 28, 2012. The original and final closing date was September 7, 2015. It was archived on October 8, 2015.
Is this funding opportunity still active?
No. Because it closed in 2015 and was archived in 2015, the announcement is no longer active for new applications under FOA number PA-12-221.
Where can someone find the full FOA text?
The full FOA text was provided via the NIH Grants Guide at: http://grants.nih.gov/grants/guide/pa-files/PA-12-221.html
Who was listed as a contact for access or linking issues?
Browse more opportunities from the same category: Education Health
Next opportunity: Women Offenders Developing an Agencywide Approach
Previous opportunity: Biomarkers for Early Detection of Hematopoietic Malignancies (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 12 221
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 12 221) also looked into and applied for these:
| Funding Opportunity |
|---|
| Cohort Studies of HIV/AIDS and Substance Use (U01) Apply for PAR 12 222 Funding Number: PAR 12 222 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Advancing Community level Approaches to Reduce HIV Infection in Highly Impacted Communities (R01) Apply for RFA MH 13 090 Funding Number: RFA MH 13 090 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Advancing Community level Approaches to Reduce HIV Infection in Highly Impacted Communities (R21) Apply for RFA MH 13 091 Funding Number: RFA MH 13 091 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Advancing Community level Approaches to Reduce HIV Infection in Highly Impacted Communities (R34) Apply for RFA MH 13 092 Funding Number: RFA MH 13 092 Agency: National Institutes of Health Category: Education Health Funding Amount: $225,000 |
| Addressing Needs of Informal Caregivers of Individuals with Alzheimers Disease in the Context of Sociodemographic Factors (R01) Apply for RFA NR 13 001 Funding Number: RFA NR 13 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| Physical activity and weight control interventions among cancer survivors Effects on biomarkers of prognosis and survival (R01) Apply for PAR 12 228 Funding Number: PAR 12 228 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Physical activity and weight control interventions among cancer survivors Effects on biomarkers of prognosis and survival (R21) Apply for PAR 12 229 Funding Number: PAR 12 229 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Translational Research on Interventions for Adolescents in the Legal System TRIALS (U01) Apply for RFA DA 13 009 Funding Number: RFA DA 13 009 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Development of Minimally Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R21) Apply for PAR 12 238 Funding Number: PAR 12 238 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Clinical Development of Minimally Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R01) Apply for PAR 12 239 Funding Number: PAR 12 239 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| NCI National Clinical Trials Network Network Radiotherapy and Imaging Core Services Centers (U24) Apply for RFA CA 12 014 Funding Number: RFA CA 12 014 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI National Clinical Trials Network Canadian Collaborating Clinical Trials Network (Limited Competition U10) Apply for RFA CA 12 504 Funding Number: RFA CA 12 504 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI National Clinical Trials Network Network Group Operations Centers (U10) Apply for RFA CA 12 010 Funding Number: RFA CA 12 010 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI National Clinical Trials Network Network Group Statistics and Data Management Centers (U10) Apply for RFA CA 12 011 Funding Number: RFA CA 12 011 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI National Clinical Trials Network Network Group Integrated Translational Science Centers (U10) Apply for RFA CA 12 012 Funding Number: RFA CA 12 012 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI National Clinical Trials Network Network Lead Academic Participating Sites (U10) Apply for RFA CA 12 013 Funding Number: RFA CA 12 013 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Behavioral Science Track Award for Rapid Transition (B/START) (R03) Apply for PAR 12 251 Funding Number: PAR 12 251 Agency: National Institutes of Health Category: Education Health Funding Amount: $75,000 |
| SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization (R44) Apply for RFA CA 12 023 Funding Number: RFA CA 12 023 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
| The Interplay of Substance Abuse and HIV 1 Infection on Glial Cell Function (R01) Apply for RFA DA 13 010 Funding Number: RFA DA 13 010 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| The Interplay of Substance Abuse and HIV 1 Infection on Glial Cell Function (R21) Apply for RFA DA 13 011 Funding Number: RFA DA 13 011 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 12 221", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.